

**PRESS RELEASE**

26 January 2023 14:30:00 CET

## Invitation to Senzime's fourth quarter 2022 report presentation

Senzime invites investors, analysts, and media to a presentation of the interim report for the fourth quarter 2022 on February 1, 14:00 CET. The report will be published at 8:30 CET the same day.

During the presentation, Senzime's CEO Pia Renaudin will present the report. A Q&A session will follow the presentation. The presentation will be held in English.

Date and time: Wednesday, February 1, 14:00 CET

The presentation can be followed live via webcast at: [Fourth Quarter Report Presentation](#)

To participate via teleconference, please dial:

From Sweden: 0200 123 717

From the UK: 0800 640 6441

From the US: 1 855 9796 654

From all other locations +44 20 39362999

The access code 077826 should be used to access the conference. Make sure you are connected to the conference call by registering a few minutes before the conference begins.

Choices for participants who want to ask questions: Press \*1 to ask a question, \*2 to withdraw your question, or \*0 for operator assistance.

After the presentation, a recording of the webcast will be available at [senzime.com](https://senzime.com).

**For further information, please contact:**

---

Pia Renaudin, CEO of Senzime AB

Phone: +46 (0) 708 13 34 17, e-mail: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

Paula Treutiger, Head of Communication and IR

Phone: +46 (0) 733 66 65 99, e-mail: [paula.treutiger@senzime.com](mailto:paula.treutiger@senzime.com)

## About Sensime

---

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Sensime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://www.senzime.com).

## Attachments

---

[Invitation to Sensime's fourth quarter 2022 report presentation](#)